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Abstract
Background: Plasma coagulation Factor XIIa (Hageman factor; encoded by F12) and kallikrein (KAL or Fletcher
factor; encoded by KLKB1) are proteases of the kallikerin-kinin system involved in converting the inactive circulating
prorenin to renin. Renin is a key enzyme in the formation of angiotensin II, which regulates blood pressure, fluid and
electrolyte balance and is a biomarker for cardiovascular, metabolic and renal function. The renin-angiotensin system is
implicated in extinction learning in posttraumatic stress disorder.
Methods & Results: Active plasma renin was measured from two independent cohorts- civilian twins and siblings, as
well as U.S. Marines, for a total of 1,180 subjects. Genotyping these subjects revealed that the carriers of the
minor alleles at the two loci- F12 and KLKB1 had a significant association with reduced levels of active plasma
renin. Meta-analyses confirmed the association across cohorts. In vitro studies verified digestion of human recombinant
pro-renin by kallikrein (KAL) to generate active renin. Subsequently, the active renin was able to digest the synthetic
substrate angiotensinogen to angiotensin-I. Examination of mouse juxtaglomerular cell line and mouse kidney
sections showed co-localization of KAL with renin. Expression of either REN or KLKB1 was regulated in cell line
and rodent models of hypertension in response to oxidative stress, interleukin or arterial blood pressure changes.
Conclusions: The functional variants of KLKB1 (rs3733402) and F12 (rs1801020) disrupted the cascade of enzymatic
events, resulting in diminished formation of active renin. Using genetic, cellular and molecular approaches we found
that conversion of zymogen prorenin to renin was influenced by these polymorphisms. The study suggests that the
variant version of protease factor XIIa due to the amino acid substitution had reduced ability to activate prekallikrein
to KAL. As a result KAL has reduced efficacy in converting prorenin to renin and this step of the pathway leading to
activation of renin affords a potential therapeutic target.
Keywords: FXIIa (active protease encoded by gene F12 or Hageman factor), Kallikrein/KAL (active protease encoded for
by gene KLKB1 or Fletcher factor), rs3733402, rs1801020, PTSD (posttraumatic stress disorder), Hypertension
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Background
Hypertension is a global public health issue and contributes
to the burden of heart disease, stroke, kidney failure and
premature mortality (13 % of total deaths worldwide)[1].
The kidney serves as a major organ for maintaining
normal blood pressure (BP) and the local renal renin
angiotensin system (RAS) pathway acts as the master
regulator of renal function during hypertension [2–4]. The
renin-angiotensin-aldosterone system (RAAS) is a signaling
pathway responsible for regulating the body's blood pres-
sure [5–8]. Stimulated by low BP the kidney releases renin,
this triggers a signal transduction pathway generating even-
tually angiotensin II that causes vasoconstriction, leading to
increase in BP. Several cardiovascular therapies for high BP,
target the RAAS system and these therapies are now being
explored for their efficacy in treating PTSD [9, 10].
The juxtaglomerular (JG) cells in the kidney express
renin a member of the aspartyl protease family. It is the
limiting enzyme in RAS pathway that converts angioten-
sinogen to angiotensin I (Ang I) [11]. Renin production
is tightly regulated at the transcriptional level and the
active renin is released into the circulation through reg-
ulated exocytosis [11, 12]. About 80 % of the renin
present in plasma is in an enzymatically inactive form
called pro-renin. Kidney processes inactive pro-renin to
renin and is the major source of circulating active renin
in humans. The plasma renin concentration contributes
significantly to cardiovascular and renal diseases like
hypertension, coronary heart disease, and chronic kidney
disease [13]. Thus the conversion of pro-renin to renin
is a potential regulatory site for therapeutic intervention.
We studied the effect of the KLKB1 (located on
chromosome 4) missense variant rs3733402 (Asn124Ser)
on circulating levels of active renin and observed that
homozygous carriers of the minor allele (Ser/Ser) dis-
played lower levels of active renin [14]. In vitro proteolysis
and cell biology indicated that pro-renin was a substrate
for plasma kallikrein (KAL). The KAL-activated renin in
turn, was able to cleave substrate angiotensinogen to
angiotensin 1 the precursor for vasoconstrictor angioten-
sin II. Situated on chromosome 5, the coagulation factor
F12 5’-UTR variant rs1801020 also showed significant as-
sociation with plasma levels of active renin. The F12 locus
encodes for the FXIIa protease responsible for converting
pre-kallikrein to KAL. The possible implication of the in-
trinsic coagulation system and the fibrinolytic system in
renin activation has been discussed. In both the independ-
ent cohorts a strong association was observed between
levels of active renin and occurrence of the minor alleles.
Methods
Twin and sibling subjects
Twin and sibling participants (TSP) for the human study
were recruited from southern California by access to a
population birth record-based twin registry [15], as well
as by newspaper advertisement [16]. The University of
California San Diego, Institutional Review Board pro-
vided approval for the study and each subject or the
parent of the minor subjects, gave written informed
consent. A subset of 381 individuals of the TSP popula-
tion was randomly selected and included 60 dizygotic
(DZ) and 160 monozygotic (MZ) twin pairs. Zygosity of
twins was confirmed genetically by use of microsatellite
and single nucleotide polymorphism (SNP) markers [16].
Initially ethnicity was established by self-identification,
including information on geographic origin of both par-
ents and all four grandparents, and only individuals of
Caucasian or Hispanic ancestry/ethnicity are included
here. The age of the subjects ranged from 14 to 78 years,
with a median of 39. Phenotyping (biochemical and
physiological) was conducted as previously described [16].
All of the 381 TSP subjects with both genotypes and phe-
notypes were included in the analyses (see below).
Molecular genetics, genomic DNA and genotyping
Genomic DNA was extracted from leukocytes in EDTA-
anticoagulated blood after proteinase-K digestion of pro-
teins, by adsorption/elution from Qiagen columns, as
previously described [16], and genotyped for 592,312
SNPs using the Illumina 610-Quad genotyping array and
passed final quality control (QC: see below). For each
MZ twin pairs, only one individual underwent GWAS,
and the genotype information was used for both mem-
bers of MZ twins. During analysis, family structure was
accounted for in MERLIN (see below).
Biochemical assay of active renin in human plasma
EDTA–anticoagulated plasma samples were collected
from seated subjects, and stored frozen at −70 °C until
assayed. Circulating active renin was quantified at room
temperature for 3 hours with a 2-site IRMA [17] wherein
the mouse monoclonal anti human renin antibody was
specific for a renin epitope formed after excision of active
renin from pro-renin (DSL, Webster, TX; DSL-25100); the
active renin assay sensitivity was ~0.48 pg/ml, with intra-
assay coefficients of variation from 1.4-4.3 %, and inter-
assay coefficients of 1.9-3.0 %.
Genetic association analyses
To test SNP on phenotype effects with explicit account-
ing for family structure for the TSP cohort, MERLIN
v1.1.2 (http://www.sph.umich.edu/csg/abecasis/merlin/)
was used. As an additional QC step, unlikely genotypes
based on expected inheritance patterns were removed
using Merlin's Pedwipe procedure. A maximum likeli-
hood estimation test of a variance components model
was used, incorporating a variance-covariance matrix
that allows for family relatedness, including twin status,
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to be modeled and appropriately controlled for in the as-
sociation test. In addition, age, gender, and the first
MDS component were included as covariates. A stand-
ard criterion of p < 5x10−8 across the genome was used
to indicate significance of single SNPs on traits. The
“Manhattan” plots visualized results across the genome,
as well as local “SNAP” (SNP Annotation and Proxy
Search) plots [18] <http://www.broadinstitute.org/mpg/
snap/ldplot.php>.
Replication Marine Resiliency Study (MRS)
We also measured active plasma renin (by ELISA) in
samples from 799 healthy unrelated male Marines from
the Marine Resiliency Study (MRS) with available geno-
types [19]. The method for genotyping of MRS subjects
has been detailed earlier [20, 21]. In brief, genotyping
was carried out using the HumanOmniExpressExome
(HOEE) array with 951,117 loci from Illumina (http://
www.illumina.com/), resulting in a high initial locus suc-
cess rate and overall data quality. Additional data clean-
ing was performed in PLINK v1.07 [22], using standard
procedures. All subjects included here were active duty
male and of European ancestry [23]. All subjects pro-
vided written consent for the genetic study. Association
of plasma renin activity with genotypes were performed
using a linear regression in PLINK (v.1.07) using age and
3 principal components (PC's) to correct for population
stratification as covariates. We used the Genetic Power
Calculator from Purcell et al. to estimate power [24].
Based on an effect size estimate of 1 % of variance ex-
plained by a candidate variant, we estimate that we had
83 % power to detect an effect of SNP on renin levels at
an alpha level of 0.05, given the number of samples
available in the MRS. Furthermore we estimate that we
would have >94 % power to detect an effect of this size
in a meta-analysis of the MRS and TSP.
Meta-analyses
Results from the TSP and MRS data were combined in
an inverse variance and weighted fixed-effect meta-
analysis was carried out using METAL [25].
Protein chemistry and enzymology
Digestion of recombinant human pro-renin by human KAL
Recombinant human pro-renin (5 μM) (Cayman Chem-
ical, catalog number 10007599) was digested with prote-
ase human KAL (kallikrein, human plasma, Calbiochem,
EMD Millipore, catalog number 420307, specific activity
15 U/mg protein) (1 μM) at 37 °C for 15 min in 12 μl of
reaction volume with assay buffer (50 mM Tris, pH 7.5,
NaCl 250 mM). The reaction was terminated by adding
aprotinin (2 μM), purified by ZipTip (small C-18 column)
and then analyzed by MALDI-TOF. For SDS-PAGE, pro-
renin was incubated in absence or presence of KAL as
mentioned above for 2 hours, and analyzed on 10 %
or 4-12 % (gradient) NuPAGE gels.
Digestion of renin substrate angiotensinogen (AGT) with
KAL-activated renin
Human pro-renin (5 μM) was digested with KAL (1 μM)
in 50 mM Tris, pH 7.5 and NaCl 250 mM in a volume
of 12 μl for 15 min at 37 °C, as mentioned above in the
first step. In the second step, 12 μl of sodium acetate
buffer, pH 5.5 containing angiotensinogen synthetic tet-
radecapeptide (14 amino acids; DRVYIHPFHL↓VIHN)
(Phoenix Pharmaceuticals, Inc.) was added (in final
concentrations of sodium acetate 0.2 M and tetradeca-
peptide 10 μM), and further incubated for another
15 min at 37 °C. The reaction digests were then purified
through ZipTip adsorption/elution, and were analyzed
by MALDI-TOF.
MALDI-TOF analysis
MALDI-TOF analyses were performed as described before
using a PE Biosystems Voyager DeSTR MALDI-TOF mass
spectrometer (Applied Biosystems, Foster City, CA) [26].
Resulting peptide masses were analyzed in the Protein-
Prospector Program (<http://prospector.ucsf.edu>) to
identify the possible fragments of the respective proteins.
Identification of active renin and pro-renin protein bands in
KAL digests, analysis by LC-MS/MS sequencing
Gel slices were cut, processed for in-gel trypsin diges-
tion and the extracted peptides were analyzed by
reverse-phase liquid chromatography (LC) in combin-
ation with tandem mass spectrometry using electro-
spray ionization with a QSTAR-Elite hybrid mass
spectrometer (AB/MDS Sciex) as described before [27].
Peptide identifications were made using the Paragon algo-
rithm executed in Protein Pilot 2.0 (Life Technologies).
Amino acid sequence analysis by TOF/TOF
Tandem mass analysis (MS/MS) for sequencing was per-
formed on a 4800 MALDI-TOF-TOF mass spectrometer
(Applied Biosystems) as described before [26].
Mouse juxtaglomerular cell culture
Mouse kidney juxtaglomerular cells As4.1 (ATCC ® CRL-
2193™) were grown in DMEM high-glucose (GIBCO) with
10 % FBS and Penicillin/streptomycin/glutamine media at
37 °C with 5 % CO2.
Co-localization of Renin and KAL by immunofluorescence
Mouse CRL-2193 (As4.1) juxtaglomerular cells
Cells were grown on cover slips, washed with PBS and
were fixed with 2.5 % paraformaldehyde in PBS for
20 min at room temperature. Cells were then perme-
abilized with 0.5 % Triton in PBS for 10 min at room
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temperature. Cells were blocked using 5 % BSA in PBS
for 30 min followed by primary antibody incubation
[rabbit anti KAL (1:100, Bioss) and goat anti renin
(1:100, Santa Cruz Biotechnology)] in 2 % BSA for 2 hr
at room temperature. Coverslips were washed 3 times
5 min each and then incubated with secondary anti-
body Alexa Fluor 488 nm (green) coupled to donkey
anti rabbit (1:250, Invitrogen) and Alexa Fluor 594 nm
(red) donkey anti goat (1:350, Invitrogen) along with
Hoechst 33342 (nuclear stain; 1 μg/mL) in 1 % BSA for
1 hr at room temperature. Coverslips were washed and
mounted on glass slide using Slowfade-antifade (Mo-
lecular Probes). Images were acquired on a Delta Vision
deconvolution microscope and SoftWorx software (Ap-
plied Precision, Issaquah, WA), using 60x objective as
described previously [28].
Mouse kidney immunohistochemistry
Formaldehyde-fixed paraffin-embedded kidney tissue sec-
tions were cleared of paraffin and hydrated through
graded alcohol and boiled in 100 °C for 20–30 min for
antigen retrieval [29]. After permeabilization and blocking,
sections were incubated overnight at 4 °C with primary
antibodies to renin and KAL, followed by incubation with
Alexa Fluor secondary antibodies as described above. Im-
ages were captured on a Delta Vision deconvolution
microscope using 20x objective.
REN and KLKB1 mRNA expression in organs and cells
Transcriptomes of mouse adrenal gland from mouse
strains blood pressure high (BPH) and blood pressure
low (BPL) (each in triplicate) [30]; rat adrenal gland
(SHR and WKY strains, each in triplicate) [31] and
mouse As4.1 juxtaglomerular cells (in duplicate) [32]
were profiled by microarray analysis as previously de-
scribed, and data are available at NCBI GEO. Data were
globally normalized to median expression, and then ana-
lyzed statistically.
Statistical analyses
The results were expressed as mean ± one SEM. Mul-
tiple comparisons were made using one-way ANOVA
followed by Bonferroni post hoc tests, or by two-way
ANOVA using Kaleidagraph (Synergy Software, Reading,
PA). Statistical significance was concluded at p < 0.05.
Results
Meta-analysis of genetic association for polymorphisms at
the F12 and KLKB1 loci and active renin concentration in
plasma
The best-characterized functional polymorphism at the
KLKB1 locus rs3733402 results in loss-of-function
amino acid substitution Asn124Ser [33]. This substitu-
tion in the apple 2 domain impairs binding and digestion
of the classical substrate HMWK (high molecular weight
kininogen) [14]. At the F12 locus, the rs1801020 poly-
morphism is in the 5’-UTR (C46T) creates a new up-
stream translational start codon, thereby attenuating
formation of the authentic F12 protease [34].
Since these proteases are part of the kallikrein-kinin
system and interact with each other at the molecular
level, we looked at genetic association of the poly-
morphisms described above with levels of active renin
in plasma. The effect of the human polymorphisms
rs3733402 in the KLKB1 locus and the rs1801020 in
F12 locus were very significant on the active renin
levels in plasma of both the TSP and MRS popula-
tions (Table 1, Fig. 1). In both cases, minor alleles
were associated with low levels of active renin in the
plasma (Fig. 1). Meta-analysis combining the TSP and
one independent population (MRS) for a total of n = 1,180
subjects, indicated allelic effects consistent in magnitude
(beta, or effect size per allele) and direction (sign on slope)
across populations. The overall slope of the meta-analysis
regression for rs3733402 and rs1801020 was beta = 0.055
and 0.057, with SE =0.014 (p = 6.83 x 10−5) and = 0.016
(p = 0.0003) respectively (Table 1).
Table 1 Meta-analysis of the effect of KLKB1 and F12 genetic polymorphisms on generation of active renin in human plasma
KLKB1 (rs3733402)
Cohort A1 A2 N BETA SE P MAF HetISq HetP G/G Freq G/A Freq A/A Freq HWE chi-square HWE-p
TSP G A 381 −0.071 0.025 0.005 0.5 20.42% 49.17% 30.42% 0.399 0.712
MRS G A 799 −0.048 0.016 0.0037 0.47 20.40% 52.82% 26.78% 2.67 0.102
Meta-analysis G A 1180 −0.055 0.014 7.22E-05 0.48 0 0.507
F12 (rs1801020)
Cohort A1 A2 N BETA SE P MAF HetISq HetP A/A Freq A/G Freq G/G Freq HWE chi-square HWE-p
TSP A G 381 −0.061 0.031 0.0459 0.23 4.58% 33.75% 61.67% 0.514 0.426
MRS A G 798 −0.055 0.018 0.0026 0.24 6.14% 35.71% 58.15% 0.339 0.0561
Meta-analysis A G 1179 −0.057 0.016 0.0003 0.24 0 0.947
A1/A2: effect allele/non-effect allele, N: sample size, BETA: estimated beta coefficient, SE: standard error of beta, P: p-value for beta, MAF: minor allele frequency,
HetP: p-value for Cochran's Q statistic, HetISq: I2 heterogeneity index, TSP: twin & sibling participants, MRS: Marine resiliency study
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Digestion of human recombinant pro-renin with kallikrein
(KAL) yields active renin and the pro-peptide byproduct
MALDI-TOF analysis of KAL digested pro-renin dis-
played two peaks of m/z 36,861 and 5100, corre-
sponding to the theoretical masses of active renin and
pro-peptide respectively (Fig. 2, lower panels). In
control reaction, where pro-renin was incubated in
absence of KAL, MS chromatogram showed a single
peak of m/z 44,255, representing the intact pro-renin
(Fig. 2, upper panel). In order to identify the se-
quence of the digested products, the digestion mix-
ture was subjected to SDS-PAGE on a 10 % gel to
separate high molecular weight pro-renin and active
renin, and on a 4-12 % gradient gel to separate low
molecular weight pro-peptide fragment. A faster mi-
grating band compared to that of pro-renin appeared
only in the KAL digested sample (Fig. 3a, marked
with arrow 2). Generation of a low molecular weight
fragment of ~ 5 kDa was evidenced after digestion of
pro-renin with KAL (Fig. 3a, right panel, marked with
arrow 3). Fragments marked with arrow 2 and 3 were
cut out from the gel, trypsin digested and subjected
to LC-MS analysis for identification. Peptides identi-
fied from gel fragment 3 showed significant coverage
on the N and C-terminal of pro-peptide sequence
(Fig. 3b), whereas same from gel fragment 2 showed
coverage on active-renin (Fig. 3b). Since LC-MS analysis
from gel fragment 3 identified some active renin sequence
and gel fragment 2 identified some pro-peptide sequence,
we quantified the data by normalizing the total sum of
spectra for pro-peptide and active renin observed in gel
fragment 2 and 3 by their amino acid length. Quantifica-
tion of mass spec data showed a significant enrichment
(400-fold) of pro-peptide to active renin ratio in gel frag-
ment 3 over gel fragment 2 (Fig. 3c).
Fig. 1 Effect of polymorphisms in the KLKB1 (Asn124Ser) and F12
(5’-UTR C46T) loci on circulating levels of active renin in UCSD
twins/siblings and in MRS subjects. Polymorphisms at F12 and KLKB1 loci
influenced plasma active renin levels in two independent cohorts civilian
and marines. Each SNP was in Hardy-Weinberg equilibrium with p> 0.05
Fig. 2 Mass spectrometric analysis of the KAL digested samples of recombinant pro-renin. Recombinant pro-renin was incubated in absence
(upper panel) or presence (middle and bottom panel) of KAL in the assay buffer as mentioned before. The digestion mixture was acidified and
purified through ZipTip and subjected to MALDI-TOF analysis in linear mode. Observed masses were compared with the theoretical mass
predicted by ProteinProspector program and are shown in the table
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KAL digested pro-renin cleaves angiotensinogen substrate
to generate angiotensin I
Active renin digests substrate angiotensinogen to gen-
erate angiotensin I (Ang I). We tested the ability of
KAL digested pro-renin to digest angiotensinogen.
The pre-angiotensinogen 1–14 tetra deca peptide
(AGT) was incubated with the KAL-digested pro-
renin. Analysis of the digestion reaction containing
AGT and KAL revealed one major peptide of m/z
1759.9 (Fig. 4a, upper panel). Incubation of pro-renin
with KAL followed by the addition of AGT generated
a major peak of m/z 1296.81 (Fig. 4a, lower panel).
MS/MS analysis of the precursor mass 1759.9 and
1296.8 confirmed the sequence of these two peptides
as amino acids 34–47 and 34–43 of human angioten-
sinogen (Fig. 4b). Quantification of MS data suggest ~
96 % generation of Ang I peptide in reaction containing
KAL, pro-renin and AGT, whereas only 24 % in presence
of pro-renin and AGT and 8 % in presence of KAL and
AGT. The generation of Ang I or AGT 1–10 peptide of
m/z 1296.8 was not detected in digestion reactions con-
taining only KAL, pro-renin, AGT or in KAL and pro-
renin combination (Fig. 4c).
Renin co-localized with KAL, in kidney JG cells and their
renin secretory granules
Immunofluorescence experiments of mouse juxtaglo-
merular cells (Fig. 5a) as well as in mouse kidney sec-
tion (Fig. 5b), was used to establish renin’s subcellular
co-localization with its processing enzyme KAL. The
immunofluorescence micrographs showed that renin
and KAL co-localized partially as evidenced by the
orange/yellow fluorescence in the overlay figures.
Pearson coefficient of co-localization was 0.15 for
As1.4 cells and 0.5 for the kidney section.
Endogenous expression of KLKB1 and REN
After confirming by in vitro assay that KAL processed
prorenin to active renin, we analyzed how the expres-
sions of KLKB1 and REN genes might be correlated
Fig. 3 Molecular mass analysis of fragments generated by KAL digestion of pro-renin; identification of active renin and pro-peptide fragments.
a Recombinant pro-renin was digested with KAL as described in Fig. 2 and subjected to SDS-PAGE; 10 % gel (left panel) for separation of active
renin from pro-renin and 4–12 % gel (right panel) for identification of lower (~5 kDa) fragment). Fragments were numbered as 1 (pro-renin), 2
(active renin) and 3 (pro-peptide). M1 and M2 are SDS-PAGE molecular weight standards in broad range and low range respectively b Fragment
2 and 3 were cut out and subjected to trypsin digestion and LC-MS/MS analysis separately for identification. Peptide coverage (bold type)
identified by MS/MS in the termini of pro-peptide (from fragment 3) and active renin (from fragment 2) is shown. c Quantification of the MS
data. The total sum of pro-peptide and active renin spectra observed were normalized by the amino acid length (43 for pro-peptide and 340
for the active renin) to represent the pro-peptide to active renin ratio in gel fragments 2 or 3
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under various physiological conditions. REN and
KLKB1 mRNA expression data were collected and an-
alyzed for in mouse As4.1 cells (Fig. 6a) and adrenal
tissues of rodent genetic hypertension models: blood
pressure low (BPL) and blood pressure high (BPH)
mouse models and normotensive Wistar-Kyoto (WKY)
and spontaneously hypertensive (SHR) rat models (Fig. 6b).
In As4.1 cells feedback inhibition of renin expression
was observed by the addition of interleukin 1-β or
hydrogen peroxide, concomitantly KLKB1 expression
remained unaltered. The hypotensive phenotype of BPL
mice triggered renin expression, ~ 4 fold higher com-
pared to hypertensive BPH mice. However the expres-
sion of KLKB1 did not differ significantly amongst BPL
and BPH mice. The normotensive WKY rats have sig-
nificantly higher KLKB1 expression (~5.5 fold) com-
pared to the hypertensive SHR rats with more or less
similar level of REN mRNA expression in both rat
models. Thus regulation of blood pressure under
various physiological conditions may involve modula-
tion in the expression of either REN or KLKB1.
Discussion
In vitro studies have demonstrated that proteases such
as trypsin, plasmin, pepsin, kallikrein and several others
activate zymogen pro-renin to active renin [35–38].
Studies before the era of mass spectroscopy suggested
involvement of KLKB1 and FXIIa in pro-renin process-
ing [39–41]. Genetic variation at the KLKB1 locus (en-
coding for plasma pre-kallikrein or Fletcher factor; EC
3.4.21.34) was previously most widely investigated for
its roles in coagulation and allergy. We demonstrate
using in vitro enzymatic assay the ability of active pro-
tease KAL in processing pro-renin→ renin. A second
association of renin activity and the protease F12 locus
(encoding for Factor XII or Hageman factor; EC
3.4.21.38) suggests a cascade of enzymatic events
Fig. 4 Generation of Ang I from renin substrate tetradecapeptide (pre-angiotensinogen 1–14) by KAL-activated pro-renin. a AGT was incubated
with KAL (upper panel) and with pro-renin and KAL (lower panel) as described in methods. The reaction digests were purified through ZipTip
and subjected to MALDI-TOF analysis. b TOF/TOF analysis of the precursor mass 1759.9 and 1296.81 c Quantification of the MS scans.
The % conversion of AGT (1–14 to 1–10) was quantified from the relative intensity of the Ang I peptide under different
experimental conditions
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(FXIIa→ KAL) in control of pro-renin activation. Gen-
eration of active renin by the cascade thus provides evi-
dence of a site for BP regulation.
The KLKB1 locus lies directly beneath a previously de-
scribed LOD peak (LOD = 3.2) for BP on chromosome 8
in the genetically hypertensive strain of mice (BPH) [42].
We therefore explored the effects of KLKB1 genetic vari-
ation upon formation of active renin. While most of the
KLKB1 single nucleotide polymorphisms (SNPs) re-
ported are located in the non-coding regions, rs3733402
A
B
Fig. 5 Co-localization of renin and KAL in a As4.1 (CRL-2193) juxtaglomerular cells and in b mouse kidney: The cells (upper two panels) and
kidney sections (lower two panels) were stained with rabbit anti-KAL primary and donkey anti-rabbit IgG- Alexa Fluor®488 conjugated secondary
(green); and goat anti-renin primary and donkey anti-goat IgG- Fluor®594 conjugated secondary (red). The nuclei were visualized with Hoechst
33342 dye (blue). A series of xy optical sections along the z-axis was acquired using a 60x oil immersion objective for cells and 20x objective for
kidney section by deconvolution microscopy and the data set was processed to generate three-dimensional (3D) or representative xy section.
Co-localization of KAL (green) and renin (red) is shown by overlay of the images (yellow fluorescence). Bar scale is 5 μM
A B
Fig. 6 Correlation of REN and KLKB1 mRNA expression in a renal juxtaglomerular cells and (B) in the adrenal glands of rodent models of
genetic hypertension (mouse: BPH/BPL and rat: SHR/WKY): REN and KLKB1 mRNA expression data were collected and compared for (a and b)
Biswas et al. BMC Medical Genetics  (2016) 17:21 Page 8 of 11
in exon 5 results in an amino acid substitution
Asn124Ser [14, 33]. This mutation in the apple
domain 2 of heavy chain reduces the binding of KAL
to its substrate HMWK, and therefore this SNP was
chosen to investigate its association with prorenin
processing. Indeed, an immunoassay specific for active
renin revealed that Ser/Ser homozygotes had lower
circulating active renin (Fig. 1), consistent with dimin-
ished pro-renin cleavage by a less active Ser allele.
Previously, rs3733402 has shown strong association
with pre-pro-endothelin-1 and pre pro-adrenomedullin in
the Prevention of Renal and Vascular End stage dis-
ease (PREVEND) study [43]. In the recent study by
Lieb et al. the top SNPs identified were rs12374220,
an intronic variant in the TENM3 gene, rs5030062 in
the intron 6 of kininogen 1 gene and rs4253311 in
intron 11 of the kallikrein B (KLKB1) gene. The in-
tronic SNP rs4253311 provided no evidence for asso-
ciation with renin concentrations and explained
0.87 % of plasma renin activity variance [44]. In our
study MALDI mass spectrometry documented the
formation of active renin and the pro-peptide after di-
gestion of pro-renin with KAL (Fig. 2 & Fig. 3). Fur-
thermore the sub-cellular co-localization of renin with
KAL suggests molecular interaction between these
two proteins (Fig. 5a &b). Renin immunoreactivity
has previously been shown in the cytoplasmic gran-
ules of cultured JG cells and in kidney sections [45].
The cleavage sites involved in pro-renin processing in-
clude lysine-arginine, which is the recognition site of
plasma kallikrein [46]. Our genetic and biochemical
data suggests an enzyme-substrate relation between
KAL and prorenin. This suggests the possible existence
of feedback regulation at the molecular level in the
events leading to active renin generation by KAL and
BP regulation.
KAL is a glycoprotein that takes part in the surface
dependent activation of blood coagulation, fibrinolysis
and kinin generation. It is synthesized in the liver and
secreted into the blood as prekallikrein, which is then
converted to active plasma kallikrein by factor FXIIa
[47]. The C46T 5’-UTR polymorphism associated with
Hageman factor has been described to be associated
with its plasma concentration and thrombotic risk
[48, 49]. The KAL protease might catalyzes the con-
version of HMWK to bradykinin in one hand, and
the active renin on other hand. The downstream tar-
get angiotensin converting enzyme (ACE) then modulates
the concentration of angiotensin II, the key player of the
RAAS system, and bradykinin, a component of the
kallikrein-kinin system in opposite direction, therefore es-
tablishing a direct interaction between kallikrein-kinin
and renin-angiotensin system [50, 51].
The genetic variation in the F12 and KLKB1 loci
directly affecting their amino acid sequence could ul-
timately influenced the processing, secretion or circu-
lation of the active renin protein, which in turn
mediates the BP phenotype. Allelic effects might also
act on the cluster of characteristics associated with
cardiovascular risk for which plasma renin is a bio-
marker. In the coagulation system, it has been re-
ported that even the homozygous deficiency of the
KLKB1 loci results in no discernible coagulopathy
[52]. In treatment of hereditary angioedema inhibition
of KAL does play a beneficial role, perhaps by inhib-
ition of bradykinin formation [53].
Fig. 7 Hypothetical schematic representing activation of pro-renin by a proteolytic enzyme cascade of FXIIa→ KAL, with consequences for
regulation of BP. Pro-renin processing within the secretory granule of renal juxtaglomerular cells by sequential enzymatic events catalyzed
by F12 and KAL
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Advantages and limitations
Here we report a comprehensive GWAS showing cor-
relation between polymorphisms at two independent
loci (KLKB1 rs3733402 and F12 rs1801020) and
plasma renin activity. Cellular and biochemical evi-
dence is provided to establish that correlation. To our
knowledge this is the first report of SNPs in two in-
dependent loci with significant trait association with
activation of renin-angiotensin system. This study fo-
cused on the best characterized SNP (rs3733402) in
the exon 5 of KLKB1 gene. Although association of
kallikrein with renin activation has previously been
described, adequate information on direct in vitro
protease biochemistry was lacking. Therefore we used
a mass spectrometry approach to characterize in vitro
digestion of prorenin by KAL to reestablish kallikrein
association with prorenin processing. In the scenario
of this genetic association, the efficacy of digestion of
prorenin by mutant KAL (Asp124Ser) needs to be
compared with that of the wild type KAL. We have
not addressed in these populations the active plasma
renin association with the previously described in-
tronic variant at KLKB1 (rs4253311) and other SNPs.
Future studies will explore the association of these
two SNPs with BP, renal and/or metabolic traits.
Conclusion
Our findings draw attention to the role of KAL as a
pro-renin convertase and suggest a potential target
for inhibition of the rate-limiting step in the RAS
pathway. Polymorphisms at the KLKB1 (rs3733402)
and F12 (rs1801020) loci are associated with low ac-
tive plasma renin activity. Genetic, cell and biochem-
ical studies suggest a cascade of enzymatic events
involving factor FXIIa activation of prekallikrein to
active kallikrein in control of pro-renin activation.
Thus plasma kallikrein presents potential as novel
therapeutic target for blood pressure regulation with
implications of KAL inhibition for treatment of
hypertension (Fig. 7).
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